Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The arenavirus envelope glycoprotein is a critical viral surface protein complex responsible for mediating host cell entry and is the primary target for neutralizing antibodies. It is synthesized as a precursor polypeptide (GPC) that undergoes complex post-translational processing to yield the mature glycoprotein components found on the virion surface. The precursor consists of three main components: Stable Signal Peptide (SSP), GP1 (the receptor-binding subunit), and GP2 (the transmembrane fusion subunit). These subunits remain non-covalently associated on the virion surface as a trimeric complex. GP1 determines host range/tropism via interaction with specific cellular receptors. Low pH induces conformational changes in GP2, enabling membrane merger. SSP modulates this process. The glycoprotein is heavily shielded by glycans, impeding effective neutralization by antibodies, contributing to persistent infection.
Direct interaction with viral envelope glycoprotein complex to inhibit host cell entry or neutralize the virus. Developmental stage therapeutics may target specific stages of GPC processing, such as SKI-1/S1P inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arenavirus Envelope Glycoprotein (GPC).